Ipca Laboratories Ltd
Company Profile
Business description
Ipca Laboratories Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company is an integrated pharmaceutical company manufacturing and marketing over 350 formulations and various API's covering various therapeutic segments. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), and Losartan. The company has only one reportable primary business segment, pharmaceuticals. Geographically, the maximum revenue is derived from outside India, mainly from Europe, Africa, the Americas, Asia, etc.
Contact
125, Kandivli Industrial Estate
Kandivli (West)
MumbaiMH400067
INDT: +91 2262105000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
23,467
Stocks News & Analysis
stocks
This former ASX tech darling is now 25% undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.90 | 14.10 | 0.15% |
| CAC 40 | 8,278.59 | 45.30 | 0.55% |
| DAX 40 | 26,347.45 | 80.26 | 0.31% |
| Dow JONES (US) | 52,231.89 | 157.86 | -0.30% |
| FTSE 100 | 10,751.59 | 31.28 | -0.29% |
| HKSE | 24,403.73 | 153.31 | -0.62% |
| NASDAQ | 25,065.87 | 187.27 | -0.74% |
| Nikkei 225 | 60,942.48 | 482.90 | 0.80% |
| NZX 50 Index | 14,162.33 | 5.08 | -0.04% |
| S&P 500 | 7,520.93 | 29.01 | -0.38% |
| S&P/ASX 200 | 9,144.00 | 15.00 | 0.16% |
| SSE Composite Index | 3,657.05 | 6.67 | -0.18% |